HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids

This publication has 40 references indexed in Scilit:

• Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  Annals of Oncology, 2020
• Hsp90 chaperones have an energetic hot‐spot for binding inhibitors
  Protein Science, 2020
• N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression
  European Journal of Medicinal Chemistry, 2020
• Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells
  Bioorganic Chemistry, 2019
• Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
  2018
• Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors
  European Journal of Medicinal Chemistry, 2018
• Designing multi-targeted agents: An emerging anticancer drug discovery paradigm
  European Journal of Medicinal Chemistry, 2017
• Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo
  Biochemical and Biophysical Research Communications, 2015
• Thermodynamics of radicicol binding to human Hsp90 alpha and beta isoforms
  Biophysical Chemistry, 2010
• Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1
  Cell, 2004